AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9674377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamometer testing for isometric strength (IS) at 90 degrees to the lateral plane
Number of subjects: 13
Study 9674377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings of perceived exertion for low back and right arm in isometric lifting
Number of subjects: 13
Study 9674377 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of dynamic forces in the dynamometer
Number of subjects: 13
Study 9674377 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength in the sagittal plane
Number of subjects: 13
Study 9674377 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength at right angles to the lateral plane
Number of subjects: 13
Study 8083076 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (200 U/kg/day) and ferrous sulfate 5‐10 days prior to initiation of external beam radiation therapy
Number of subjects: 20
Study 8083076 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate alone
Number of subjects: 20
Study 8083076 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 20
Study 2754150 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5% saline nebulization
Number of subjects: 0
Study 2754150 — intervention group
Group type: COMPARATOR
Intervention: Histamine challenge
Number of subjects: 0
Study 2754150 — intervention group
Group type: COMPARATOR
Intervention: Isocapneic hyperventilation
Number of subjects: 0
Study 2754150 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of 4.5% saline via higher output nebulizer
Number of subjects: 0
Study 55650 — intervention group
Group type: EXPERIMENTAL
Intervention: Lippes Loop
Number of subjects: 279
Study 55650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon Shield
Number of subjects: 279
Study 55650 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper 7
Number of subjects: 279
Study 55650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalkon Shield (small size) for nulliparae
Number of subjects: 279
Study 55650 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper 7 for nulliparae
Number of subjects: 279
Study 31113007 — intervention group
Group type: EXPERIMENTAL
Intervention: GLICEMIA intervention (3 individual counseling sessions and 5 group-based lectures)
Number of subjects: 1087
Study 31113007 — intervention group
Group type: EXPERIMENTAL
Intervention: GLICEMIA intervention
Number of subjects: 1087
Study 31113007 — intervention group
Group type: COMPARATOR
Intervention: Control group (reduced standard information)
Number of subjects: 1087
Study 31113007 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1087
Study 31005385 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (40 mg/kg over 5 min)
Number of subjects: 286
Study 31005385 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (20 mg/kg over at least 20 min)
Number of subjects: 286
Study 31005385 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 286
Study 31005385 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 286
Study 28065961 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cross-friction massage for 30 minutes, 5 times a week for 6 weeks
Number of subjects: 60
Study 28065961 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy (Control)
Number of subjects: 60
Study 28065961 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cross-friction massage
Number of subjects: 60
Study 25811584 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% inhaled oxygen
Number of subjects: 46
Study 25811584 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 46
Study 23789452 — intervention group
Group type: EXPERIMENTAL
Intervention: hilifox‐750 (750 mg daily for 5 days)
Number of subjects: 60
Study 23789452 — intervention group
Group type: COMPARATOR
Intervention: amoxiclav (875/125 mg twice daily for 10 days)
Number of subjects: 60
Study 23789452 — intervention group
Group type: EXPERIMENTAL
Intervention: hilifox‐750
Number of subjects: 60
Study 20696676 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Number of subjects: 70
Study 20696676 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy with cisplatin-docetaxel (D 75 mg/m² on day 1 and C 40 mg/m² on days 1 and 2) followed by concurrent chemoradiotherapy (66 Gy with weekly D 20 mg/m² and C 20 mg/m²)
Number of subjects: 70
Study 20696676 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 70
Study 20696676 — intervention group
Group type: COMPARATOR
Intervention: Consolidation chemotherapy
Number of subjects: 70
Study 20696676 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 70
Study 18295109 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (UGFS)
Number of subjects: 89
Study 18295109 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided liquid sclerotherapy (UGLS)
Number of subjects: 89
Study 16809947 — intervention group
Group type: EXPERIMENTAL
Intervention: Medilac DS (Bacillus subtilis, Streptococcus faecium)
Number of subjects: 40
Study 16809947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12634224 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA plus MTX combination therapy
Number of subjects: 120
Study 12634224 — intervention group
Group type: COMPARATOR
Intervention: CsA monotherapy
Number of subjects: 120
Study 10719408 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based dietary fat intake intervention (11 lessons over 14 weeks)
Number of subjects: 110
Study 10719408 — intervention group
Group type: COMPARATOR
Intervention: Pretest/posttest control group (no specific intervention mentioned)
Number of subjects: 110
Study 9367069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral retinol (25,000 IU) daily for up to 5 years
Number of subjects: 2297
Study 9367069 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 2297
Study 1588378 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 237
Study 1588378 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy plus radiation
Number of subjects: 237
Study 1588378 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated breast
Number of subjects: 237
Study 1588378 — intervention group
Group type: EXPERIMENTAL
Intervention: Local breast failures
Number of subjects: 237
Study 3866866 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly mouthrinsing with a 0.2 percent NaF solution
Number of subjects: 425
Study 3866866 — intervention group
Group type: COMPARATOR
Intervention: Control group (semiannual fluoride varnish treatments)
Number of subjects: 425
Study 28843837 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided intervention
Number of subjects: 51
Study 28843837 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 51
Study 27612046 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospectively ECG-triggered acquisition CCTA at 100 kVp (Group A)
Number of subjects: 120
Study 27612046 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive prospective ECG-triggered sequence acquisition at 100 kVp (Group B)
Number of subjects: 120
Study 27612046 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive prospective ECG-triggered sequence acquisition at 80 kVp with iterative reconstruction (Group C)
Number of subjects: 120
Study 25219106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with wheat, up-dosing phase until 100 g tolerated, followed by 6-month maintenance phase
Number of subjects: 6
Study 25219106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with wheat
Number of subjects: 6
Study 22872467 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg E(2)
Number of subjects: 16
Study 20968271 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (1 g/d for 6 weeks)
Number of subjects: 58
Study 20968271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18303020 — intervention group
Group type: EXPERIMENTAL
Intervention: sifuvirtide (5, 10, 20, 30, and 40 mg) by subcutaneous injection once daily
Number of subjects: 60
Study 18303020 — intervention group
Group type: COMPARATOR
Intervention: Enfuvirtide (T20)
Number of subjects: 60
Study 16008680 — intervention group
Group type: COMPARATOR
Intervention: Secretor subjects (Se/Se)
Number of subjects: 297
Study 16008680 — intervention group
Group type: COMPARATOR
Intervention: Blood group O/secretor phenotype (Se/Se)
Number of subjects: 297
Study 16008680 — intervention group
Group type: COMPARATOR
Intervention: Blood group O/Le(a-b-)
Number of subjects: 297
Study 16008680 — intervention group
Group type: COMPARATOR
Intervention: Lewis Le(a-b-) recessive genotype
Number of subjects: 297
Study 16008680 — intervention group
Group type: COMPARATOR
Intervention: Joint blood group O/Le(a-b-) phenotype
Number of subjects: 297
Study 12747278 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prednisone daily
Number of subjects: 81
Study 12747278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 11191780 — intervention group
Group type: EXPERIMENTAL
Intervention: Error training
Number of subjects: 0
Study 11191780 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided error training
Number of subjects: 0
Study 11191780 — intervention group
Group type: COMPARATOR
Intervention: Errorless learning
Number of subjects: 0
Study 8615348 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy, high-protein drink (atole)
Number of subjects: 460
Study 8615348 — intervention group
Group type: COMPARATOR
Intervention: Low-energy, no-protein drink (fresco)
Number of subjects: 460
Study 1360774 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate, 12 micrograms, bid
Number of subjects: 112
Study 1360774 — intervention group
Group type: COMPARATOR
Intervention: Switch from salbutamol to formoterol
Number of subjects: 112
Study 4061119 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction program (W group, n = 24)
Number of subjects: 64
Study 4061119 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and salt reduction program (WS group, n = 23)
Number of subjects: 64
Study 4061119 — intervention group
Group type: COMPARATOR
Intervention: Salt restriction program (S group, n = 17)
Number of subjects: 64
Study 4061119 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction program (W group)
Number of subjects: 64
Study 4061119 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight and salt reduction program (WS group)
Number of subjects: 64
Study 4061119 — intervention group
Group type: COMPARATOR
Intervention: Salt restriction program (S group)
Number of subjects: 64
Study 30616570 — intervention group
Group type: EXPERIMENTAL
Intervention: non-invasive vagus nerve stimulation (nVNS)
Number of subjects: 0
Study 30616570 — intervention group
Group type: COMPARATOR
Intervention: sham control
Number of subjects: 0
Study 27534447 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-titanium stent as a facial pressure bearing device
Number of subjects: 24
Study 27534447 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing (control group)
Number of subjects: 24
Study 25382826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodrug (LY2140023) 80 mg oral
Number of subjects: 0
Study 25382826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodrug (LY2140023) 80 mg oral and 100 μg i.v.
Number of subjects: 0
Study 25382826 — intervention group
Group type: EXPERIMENTAL
Intervention: Active moiety (LY404039) 100 μg i.v.
Number of subjects: 0
Study 25382826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodrug (LY2140023)
Number of subjects: 0
Study 24342198 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (HFOV, PS, iNO)
Number of subjects: 116
Study 24342198 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (HFOV, iNO)
Number of subjects: 116
Study 21621753 — intervention group
Group type: EXPERIMENTAL
Intervention: Two faces looking at each other
Number of subjects: 0
Study 21621753 — intervention group
Group type: COMPARATOR
Intervention: Two faces looking away from each other
Number of subjects: 0
Study 19363561 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 62
Study 19363561 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 62
Study 19363561 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 62
Study 16460632 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel covered with Tegaderm
Number of subjects: 200
Study 16460632 — intervention group
Group type: COMPARATOR
Intervention: Cutiplast
Number of subjects: 200
Study 15308252 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle handling of soft tissues on the medial side of the ascending ramus (test side)
Number of subjects: 0
Study 15308252 — intervention group
Group type: COMPARATOR
Intervention: Routine handling of soft tissues (contralateral control side)
Number of subjects: 0
Study 11499744 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (15 g daily)
Number of subjects: 40
Study 11499744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9988941 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing with optimum AV delay
Number of subjects: 9
Study 9988941 — intervention group
Group type: COMPARATOR
Intervention: VVI mode at ventricular 'sentinel' rate of 50 b/min
Number of subjects: 9
Study 7528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment in 17 children
Number of subjects: 30
Study 7528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed viremia (wild-type and HBeAg minus HBV) in 10 children (34.5%)
Number of subjects: 30
Study 7528908 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg minus HBV
Number of subjects: 30
Study 7528908 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type HBV
Number of subjects: 30
Study 3372288 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal education program
Number of subjects: 28
Study 29703591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-initiated radiographic-test protocol (using Ottawa Ankle Rules)
Number of subjects: 112
Study 29703591 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (physician expertise)
Number of subjects: 112
Study 28258526 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication advertisement
Number of subjects: 424
Study 28258526 — intervention group
Group type: COMPARATOR
Intervention: Automobile advertisement
Number of subjects: 424
Study 25311256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Number of subjects: 88
Study 25311256 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 88
Study 23132508 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT)
Number of subjects: 85
Study 23132508 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (Control)
Number of subjects: 85
Study 21575074 — intervention group
Group type: EXPERIMENTAL
Intervention: CwPLI
Number of subjects: 71
Study 21575074 — intervention group
Group type: COMPARATOR
Intervention: CwSLI
Number of subjects: 71
Study 21575074 — intervention group
Group type: EXPERIMENTAL
Intervention: CwPLI and CwSLI
Number of subjects: 71
Study 19626555 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17009253 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of sCT
Number of subjects: 41
Study 17009253 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of sCT
Number of subjects: 41
Study 17009253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15015948 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnet attachments
Number of subjects: 18
Study 15015948 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar-clip attachments
Number of subjects: 18
Study 15015948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball attachments
Number of subjects: 18
Study 10680410 — intervention group
Group type: EXPERIMENTAL
Intervention: BSE skills-building workshop
Number of subjects: 0
Study 10680410 — intervention group
Group type: COMPARATOR
Intervention: Matched sexually transmitted diseases prevention workshop
Number of subjects: 0
Study 9077495 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyositis (PM) patients
Number of subjects: 14
Study 9077495 — intervention group
Group type: COMPARATOR
Intervention: Other neuromuscular diseases (ONMD) patients
Number of subjects: 14
Study 9077495 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha positive muscles
Number of subjects: 14
Study 8447841 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunoassay (RIA)
Number of subjects: 51
Study 8447841 — intervention group
Group type: COMPARATOR
Intervention: Gas Chromatographic/Mass Spectrometric (GC/MS)
Number of subjects: 51
Study 8447841 — intervention group
Group type: EXPERIMENTAL
Intervention: High Pressure Liquid Chromatography (HPLC) combined with RIA
Number of subjects: 51
Study 8447841 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifications of the radioimmunoassay procedure
Number of subjects: 51
Study 3114548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupranolol 100 mg
Number of subjects: 20
Study 3114548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29972647 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (monthly treatment)
Number of subjects: 702
Study 27018941 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100mg bid)
Number of subjects: 258
Study 27018941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 24029546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral laquinimod (0.6 mg)
Number of subjects: 1106
Study 24029546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1106
Study 22939094 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated formats (text/numbers, pie chart, bar graph, pictograph)
Number of subjects: 100
Study 22939094 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference match (format matched to individual preference)
Number of subjects: 100
Study 20503023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin (800-1200 mg/d)
Number of subjects: 219
Study 18154911 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week graded exercise program
Number of subjects: 34
Study 18154911 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 34
Study 16802892 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (experimental condition)
Number of subjects: 300
Study 16802892 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 300
Study 14617458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian surgery (including unilateral oophorectomy, ovarian wedge resection, and ovarian drilling)
Number of subjects: 19
Study 14617458 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study 10882164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron monotherapy
Number of subjects: 0
Study 10882164 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone and tropisetron
Number of subjects: 0
Study 10882164 — intervention group
Group type: COMPARATOR
Intervention: High dose metoclopramide plus dexamethasone
Number of subjects: 0
Study 10882164 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron and ondansetron
Number of subjects: 0
Study 10882164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 0
Study 9496217 — intervention group
Group type: EXPERIMENTAL
Intervention: methohexitone-alfentanil
Number of subjects: 24
Study 9496217 — intervention group
Group type: COMPARATOR
Intervention: methohexitone
Number of subjects: 24
Study 9496217 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-alfentanil
Number of subjects: 24
Study 9496217 — intervention group
Group type: COMPARATOR
Intervention: propofol
Number of subjects: 24
Study 8439022 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (30 micrograms/kg)
Number of subjects: 100
Study 8439022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8439022 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual group (days 1-8)
Number of subjects: 100
Study 8439022 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmenstrual group (days 9-28)
Number of subjects: 100
Study 3513644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine (SP)
Number of subjects: 198
Study 3513644 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 198
Study 3513644 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine
Number of subjects: 198
Study 31784365 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich platelet-rich plasma (PRP) injection
Number of subjects: 97
Study 31784365 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (Control)
Number of subjects: 97
Study 30528317 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin ointment (2%) dressings
Number of subjects: 150
Study 30528317 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressings
Number of subjects: 150
Study 28753098 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CM
Number of subjects: 68
Study 28753098 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + EMD
Number of subjects: 68
Study 28753098 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CM + EMD
Number of subjects: 68
Study 28753098 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 68
Study 25510856 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CYP3A4 inhibitor)
Number of subjects: 24
Study 25510856 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin + Paroxetine (CYP3A4 + CYP2D6 inhibitors)
Number of subjects: 24
Study 25510856 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 24
Study 25510856 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐desmethylvenlafaxine/venlafaxine > 4
Number of subjects: 24